Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid

Frederick Wittke^a*, Catherine Vincent^a, James Chen^b, Barry Heller^c, Heidi Kabler^d, J. Scott Overcash^e, François Leylavergne^a, Guennaelle Dieppois^a

Antimicrobial Agents and Chemotherapy, Vol. 64, Issue 10

^aDebiopharm International SA, Lausanne, Switzerland
^bSouthbay Pharma Research, Buena Park, California, USA
^cLong Beach Clinical Trials, Long Beach, California, USA
^dSunrise Hospital and Medical Center, Las Vegas, Nevada, USA
^eeStudySite, San Diego, California, USA

*Present address: Frederick Wittke, European Clinical Development Vaccines MSD, Weystrasse 20,
6006 Lucerne, Switzerland